Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Phenothiazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.94 |
| ▸ | NOX1 | Q9Y5S8 | 10/20 | 0.94 |
| ▸ | MAPT | P10636 | 7/20 | 0.94 |
| ▸ | GAA | P10253 | 6/20 | 0.94 |
| ▸ | MEN1 | O00255 | 3/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.94 |
| ▸ | BCHE | P06276 | 3/20 | 0.94 |
| ▸ | SNCA | P37840 | 3/20 | 0.94 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.94 |
| ▸ | POLB | P06746 | 1/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.94 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.94 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.94 |
| ▸ | MAOA | P21397 | 1/20 | 0.94 |
| ▸ | CNR1 | P21554 | 1/20 | 0.94 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.94 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.94 |
| ▸ | HTR2C | P28335 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenothiazine SCHEMBL23683396 | 1.00 | NOX1 (0.94) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL3710040 | 1.00 | NOX1 (0.94) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL11406924 | 1.00 | NOX1 (0.94) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL1470980 | 1.00 | NOX1 (0.94) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL3710037 | 1.00 | NOX1 (0.94) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL1146711 | 0.97 | NOX1 (0.90) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL2504207 | 0.97 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL6315328 | 0.97 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL29349533 | 0.97 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL29352248 | 0.97 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891367-B2 | Method for preparing 3,7-bis(dimethylamino)phenothiazin-5-ylium iodide | PROVEPHARM LIFE SOLUTIONS (FR) | 2024-02-06 | — | — | US | disclosed |
| US-20210323937-A1 | METHOD FOR PREPARING 3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-YLIUM IODIDE | PROVEPHARM LIFE SOLUTIONS (FR) | 2021-10-21 | — | — | US | disclosed |
| US-11078169-B2 | Method for preparing 3,7-bis(dimethylamino)phenothiazin-5-ylium iodide | PROVEPHARM LIFE SOLUTIONS (FR) | 2021-08-03 | — | — | US | disclosed |
| US-9540405-B2 | Diaminophenothiazinium derivatives for labelling biomolecules, method and substrate for labelling oligonucleotides, and oligonucleotides obtained | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2017-01-10 | — | — | US | disclosed |
| US-20150011712-A1 | DIAMINOPHENOTHIAZINIUM DERIVATIVES FOR LABELLING BIOMOLECULES, METHOD AND SUBSTRATE FOR LABELLING OLIGONUCLEOTIDES, AND OLIGONUCLEOTIDES OBTAINED | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2015-01-08 | — | — | US | disclosed |
| US-20110306576-A1 | COMPOUNDS AND METHODS RELATING THERETO | PHARMALUCIA LIMITED (GB) | 2011-12-15 | — | — | US | disclosed |
| WO-2010097626-A2 | COMPOUNDS AND METHODS RELATING THERETO | PHARMALUCIA LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011712-A1 | DIAMINOPHENOTHIAZINIUM DERIVATIVES FOR LABELLING BIOMOLECULES, METHOD AND SUBSTRATE FOR LABELLING OLIGONUCLEOTIDES, AND OLIGONUCLEOTIDES OBTAINED | POLRMT, RNASEH1, PDXK | ACHE 2906/4885NOX1 955/4885MAPT 2623/4885 |
| US-11078169-B2 | Method for preparing 3,7-bis(dimethylamino)phenothiazin-5-ylium iodide | PIR, NISCH, INMT | ACHE 877/4885NOX1 3494/4885MAPT 521/4885 |
| US-20210323937-A1 | METHOD FOR PREPARING 3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-YLIUM IODIDE | PIR, NISCH, INMT | ACHE 877/4885NOX1 3494/4885MAPT 521/4885 |
| US-20110306576-A1 | COMPOUNDS AND METHODS RELATING THERETO | QSOX1, PYM1, SQOR | ACHE 1759/4885NOX1 94/4885MAPT 4492/4885 |
| US-11891367-B2 | Method for preparing 3,7-bis(dimethylamino)phenothiazin-5-ylium iodide | PIR, NISCH, INMT | ACHE 877/4885NOX1 3494/4885MAPT 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.